评价MS-553治疗复发或难治性B细胞淋巴瘤（BCL）患者的安全性和耐受性；确定最大耐受剂量（MTD）或临床二期推荐剂量（RP2D）；初步评价MS-553治疗复发或难治性B细胞淋巴瘤（BCL）患者的有效性；初步评价MS-553治疗复发或难治性套细胞淋巴瘤（MCL）患者的有效性；评价MS-553的药代动力学特征；探索生物标志物与MS-553治疗的疗效的相关性。

[Translation]

To evaluate the safety and tolerability of MS-553 in the treatment of patients with relapsed or refractory B-cell lymphoma (BCL); to determine the maximum tolerated dose (MTD) or recommended dose for Phase II clinical trials (RP2D); to preliminarily evaluate the efficacy of MS-553 in the treatment of patients with relapsed or refractory B-cell lymphoma (BCL); to preliminarily evaluate the efficacy of MS-553 in the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL); to evaluate the pharmacokinetic characteristics of MS-553; and to explore the correlation between biomarkers and the efficacy of MS-553 treatment.

Start Date07 Feb 2023

Sponsor / Collaborator

MingSight Pharmaceuticals, Inc.

NCT05720052 / TerminatedPhase 1/2

A Phase I/II Study to Evaluate the Safety and Efficacy of the MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except malignant lymphoblastic lymphoma (LBL) and Burkitt lymphoma. After the RP2D is identified, Phase II of subjects with relapsed or refractory mantle cell lymphoma who previously received ≥ 2 and ≤ 4 different chemotherapy and/or targeted drug therapy will be enrolled.

Start Date06 Feb 2023

Sponsor / Collaborator

MingSight Pharmaceuticals, Inc.

[+1]

NCT05272813 / TerminatedPhase 1/2

A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

Start Date28 Apr 2022

Sponsor / Collaborator

MingSight Pharmaceuticals, Inc.

100 Clinical Results associated with Sellekstaurin

100 Translational Medicine associated with Sellekstaurin

100 Patents (Medical) associated with Sellekstaurin

News (Medical) associated with Sellekstaurin

29 May 2023

·www.prnewswire.com

Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain | DelveInsight

The prevalence of diabetic retinopathy has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of diabetic retinopathy and the growing research and development activities to develop novel therapies to treat diabetic retinopathy to drive the market. The companies developing the potential therapies in the last stage of development include Roche, Kodiak Sciences, Novartis, and several others. LAS VEGAS, May 29, 2023 /PRNewswire/ -- DelveInsight's ' Diabetic Retinopathy Pipeline Insight – 2023 ' report provides comprehensive global coverage of pipeline diabetic retinopathy therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the diabetic retinopathy pipeline domain. Key Takeaways from the Diabetic Retinopathy Pipeline Report DelveInsight's diabetic retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for diabetic retinopathy treatment. Key diabetic retinopathy companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, and others are evaluating new diabetic retinopathy drugs to improve the treatment landscape. Promising diabetic retinopathy pipeline therapies in various stages of development include KSI-301, Brolucizumab, RGX 314, OTT-166, OTX-TKI, Runcaciguat, RC 28 E, RG7774, APX3330, ADVM-022, Faricimab, BI 764524, PL8331, OPL-0401, EYP-1901, emixustat hydrochloride, MS-553, THR-149, AR-13503, AXT107, OCU200, D 4517.2, Elamipretide, and others. In May 2023, Oculic Holding AG announced positive top-line results from Stage 1 of its Phase III DIAMOND trial of OCS-01 eye drops in diabetic macular edema (DME). According to the company, the DIAMOND trial in diabetic macular edema with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significance. In April 2023, Palatin Technologies announced The International Journal of Molecular Sciences published a manuscript, "Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina" by Tat Fong Ng and Andrew W. Taylor from Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, in Boston, Massachusetts. The manuscript summarizes data demonstrating the effects of PL8331 in two mouse models of retinal disease, experimental autoimmune uveoretinitis (EAU) and diabetic retinopathy (DR). Palatin and the National Institute of Health (NIH) and the Massachusetts Lions Eye Research Foundation provided funding for the study. In February 2023, Ocugen announced that it had submitted an Investigational New Drug application (IND) with the US Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of OCU200, a fusion protein with a distinct mechanism of action (MOA), for the treatment of diabetic macular edema (DME). This regulatory milestone fulfills the Company's commitment to file the IND for OCU200 within the first quarter of 2023. In January 2023, Ocuphire Pharma announced topline efficacy and safety results from its ZETA-1 Phase II trial evaluating oral APX3330 for the treatment of diabetic retinopathy (DR). Oral APX3330 demonstrated favorable safety and tolerability allowing for a potential attractive non-invasive option for protection of vision in both eyes in DR patients. In May 2022, EyePoint Pharmaceuticals announced the EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau, and Taiwan. EyePoint retains all rights for EYP-1901 in the rest of the world and expands its exclusive rights to local delivery of vorolanib for the treatment of all ophthalmic diseases, including diabetic macular edema (DME). Request a sample and discover the recent advances in diabetic retinopathy drug treatment @ Diabetic Retinopathy Pipeline Report The diabetic retinopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage diabetic retinopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the diabetic retinopathy clinical trial landscape. Diabetic Retinopathy Overview Diabetic retinopathy is a microvascular condition caused by diabetes mellitus's long-term effects. Diabetic retinopathy can cause vision-threatening retinal damage, eventually leading to blindness. It is found in one-third of patients with diabetes and is linked to an increased risk of life-threatening systemic vascular consequences such as stroke, coronary heart disease, and heart failure. Diabetic retinopathy affects an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) of people with type 1 diabetes in the United States. The keys to avoiding diabetic retinopathy blindness are early detection and appropriate intervention. Several large studies have found that the onset of diabetic retinopathy does not usually occur within the first 5 years of type 1 diabetes diagnosis. In contrast, the onset of type 2 diabetes is frequently more subtle, and as a result, retinal damage may be evident at the time of diagnosis. As a result, screening for diabetic retinopathy is advised in type 2 diabetics at the time of diagnosis. Find out more about drugs for diabetic retinopathy @ New Diabetic Retinopathy Drugs A snapshot of the Diabetic Retinopathy Pipeline Drugs mentioned in the report: Learn more about the emerging diabetic retinopathy pipeline therapies @ Diabetic Retinopathy Clinical Trials Diabetic Retinopathy Therapeutics Assessment The diabetic retinopathy pipeline report proffers an integral view of diabetic retinopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Diabetic Retinopathy Pipeline Report Coverage: Global Diabetic Retinopathy Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Diabetic Retinopathy Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Diabetic Retinopathy Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Diabetic Retinopathy Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Diabetic Retinopathy Therapeutics Assessment By Mechanism of Action: Vascular endothelial growth factors inhibitors, Angiogenesis inhibitors, Vascular endothelial growth factor A inhibitors, Gene transference, Integrin alphaVbeta3 antagonists, Integrin alphaVbeta6 inhibitors, Integrin alphavbeta8 inhibitors, Platelet-derived growth factor beta receptor antagonists, Protein tyrosine kinase inhibitors, Proto oncogene protein c-kit inhibitors, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists, Guanylate cyclase stimulants, APEX1 protein inhibitors, DNA apurinic apyrimidinic site lyase inhibitors Key Diabetic Retinopathy Companies: Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, and others. Key Diabetic Retinopathy Pipeline Therapies: KSI-301, Brolucizumab, RGX 314, OTT-166, OTX-TKI, Runcaciguat, RC 28 E, RG7774, APX3330, ADVM-022, Faricimab, BI 764524, PL8331, OPL-0401, EYP-1901, emixustat hydrochloride, MS-553, THR-149, AR-13503, AXT107, OCU200, D 4517.2, Elamipretide, and others. Dive deep into rich insights for new drugs for diabetic retinopathy treatment; visit @ Diabetic Retinopathy Medications Table of Contents For further information on the diabetic retinopathy pipeline therapeutics, reach out @ Diabetic Retinopathy Drug Treatment Related Reports Diabetic Retinopathy Market Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic retinopathy companies, including Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, among others. Diabetic Retinopathy Epidemiology Forecast Diabetic Retinopathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and diabetic retinopathy epidemiology trends. Proliferative Diabetic Retinopathy Pipeline Proliferative Diabetic Retinopathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key proliferative diabetic retinopathy companies, including Kubota Vision, among others. Diabetic Neuropathy Pipeline Diabetic Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, among others. Diabetic Neuropathy Market Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, among others. Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Clinical ResultPhase 1Phase 3

08 Mar 2023

·www.businesswire.com

Diabetic Retinopathy Pipeline Research Report 2022: Featuring Insights on 60+ Companies and Drugs in the Sector - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Diabetic Retinopathy - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering. This "Diabetic Retinopathy - Pipeline Insight, 2022" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Diabetic Retinopathy Understanding Diabetic Retinopathy: Overview Diabetic Retinopathy Emerging Drugs Chapters This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Diabetic Retinopathy Emerging Drugs KSI-301: Kodiak Sciences The Therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in diabetic retinopathy do not meet the promise shown in clinical trials. By extending on mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every four to six-month treatment regimen - a possible gamechanger that may provide the opportunity for real prevention. Brolucizumab: Novartis Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat Diabetic Retinopathy. RGX 314: Regenxbio Inc. RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDETM, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314. Diabetic Retinopathy: Therapeutic Assessment This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Diabetic Retinopathy There are approx. 60+ key companies which are developing the therapies for Diabetic Retinopathy. The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak Sciences Phases The report covers around 60+ products under different phases of clinical development like Late-stage products (Phase III ) Mid-Stage products (Phase II) Early-stage products ( Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates ^- Route of Administration Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Oral Molecule Type Products have been categorized under various Molecule types such as Small molecules Peptide Antibiotics Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Diabetic Retinopathy: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Retinopathy drugs. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Retinopathy. Diabetic Retinopathy Report Insights Diabetic Retinopathy Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Diabetic Retinopathy Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Diabetic Retinopathy drugs? How many Diabetic Retinopathy drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Retinopathy? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Retinopathy therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Diabetic Retinopathy and their status? What are the key designations that have been granted to the emerging drugs? Key Products KSI-301 Brolucizumab Runcaciguat RC 28 E AKB-9778 RG7774 RGX-314 APX3330 ADVM-022 THR-687 OCX 063 BI 764524 MS-553 A selection of companies mentioned in this report includes Ascentage Pharma AptaBio BONAC corporation CCRP Therapeutics Curacle Co Ltd Emerald Bioscience, Inc. EnnovaBio Everglades Biopharma LUYE PHARMA MIRAE CELL BIO Novelty Nobility Inc Noveome Biotherapeutics, Inc. Palatin Technologies Inc PharmAbcine Inc PYC Therapeutics Retinset SL RIBOMIC Shanghai Henlius Biotech OccuRx Kodiak Sciences Novartis Bayer RemeGen Aerpio Therapeutics Hoffman-La-Roche Regenxbio Inc. Ocuphire Pharma, Inc. Adverum Biotechnologies Oxurion MingSight Relin Pharmaceuticals Boehringer Ingelheim NovaGo Therapeutics HanAll Biopharma For more information about this clinical trials report visit https://www.researchandmarkets.com/r/vy3xvo About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Phase 2Phase 3

16 Nov 2022

·www.businesswire.com

Diabetic Retinopathy Drug Pipeline Market Insights Report 2022 - Comprehensive Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Diabetic Retinopathy - Pipeline Insight, 2022" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Diabetic Retinopathy Emerging Drugs Chapters This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Diabetic Retinopathy Emerging Drugs KSI-301: Kodiak Sciences The Therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in diabetic retinopathy do not meet the promise shown in clinical trials. By extending on mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every four to six-month treatment regimen - a possible gamechanger that may provide the opportunity for real prevention. Brolucizumab: Novartis Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat Diabetic Retinopathy. RGX 314: Regenxbio Inc. RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDETM, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314. Diabetic Retinopathy: Therapeutic Assessment This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Diabetic Retinopathy There are approx. 60+ key companies which are developing the therapies for Diabetic Retinopathy. The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak Sciences Phases This report covers around 60+ products under different phases of clinical development like Late-stage products (Phase III ) Mid-Stage products (Phase II) Early-stage products ( Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Oral Molecule Type Products have been categorized under various Molecule types such as Small molecules Peptide Antibiotics Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Diabetic Retinopathy: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Retinopathy drugs. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Retinopathy. Diabetic Retinopathy Report Insights Diabetic Retinopathy Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Diabetic Retinopathy Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: How many companies are developing Diabetic Retinopathy drugs? How many Diabetic Retinopathy drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Retinopathy? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Retinopathy therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Diabetic Retinopathy and their status? What are the key designations that have been granted to the emerging drugs? Key Players Kodiak Sciences Novartis Bayer RemeGen Aerpio Therapeutics Hoffman-La-Roche Regenxbio Inc. Ocuphire Pharma, Inc. Adverum Biotechnologies Oxurion MingSight Relin Pharmaceuticals Boehringer Ingelheim NovaGo Therapeutics HanAll Biopharma Ascentage Pharma AptaBio BONAC corporation CCRP Therapeutics Curacle Co Ltd Emerald Bioscience, Inc. EnnovaBio Everglades Biopharma LUYE PHARMA MIRAE CELL BIO Novelty Nobility Inc Noveome Biotherapeutics, Inc. Palatin Technologies Inc PharmAbcine Inc PYC Therapeutics Retinset SL RIBOMIC Shanghai Henlius Biotech OccuRx Key Products KSI-301 Brolucizumab Runcaciguat RC 28 E AKB-9778 RG7774 RGX-314 APX3330 ADVM-022 THR-687 OCX 063 BI 764524 MS-553 For more information about this report visit https://www.researchandmarkets.com/r/lg24xg

Phase 2Phase 3

100 Deals associated with Sellekstaurin

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-cell lymphoma recurrent	Phase 2	CN	MingSight Pharmaceuticals, Inc.	06 Feb 2023
B-cell lymphoma refractory	Phase 2	CN	MingSight Pharmaceuticals, Inc.	06 Feb 2023
Diffuse Large B-Cell Lymphoma	Phase 2	CN	MingSight Pharmaceuticals, Inc.	06 Feb 2023
Follicular Lymphoma	Phase 2	CN	MingSight Pharmaceuticals, Inc.	06 Feb 2023
Mantle cell lymphoma refractory	Phase 2	CN	MingSight Pharmaceuticals, Inc.	06 Feb 2023
Marginal Zone B-Cell Lymphoma	Phase 2	CN	MingSight Pharmaceuticals, Inc.	06 Feb 2023
Chronic Lymphocytic Leukemia	Phase 2	US	MingSight Pharmaceuticals, Inc.	25 May 2018
Lymphoma	Phase 2	US	MingSight Pharmaceuticals, Inc.	25 May 2018
Small Lymphocytic Lymphoma	Phase 2	US	MingSight Pharmaceuticals, Inc.	25 May 2018
Diabetic macular oedema	Phase 1	CN	MingSight Pharmaceuticals, Inc.	02 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03492125 (ASH 12022 \| ASH 22022) Manual	Phase 1/2	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	45	MS-553 (Cohort A)	ueielcznwk(kznpqohpzk) = The most common (>10%) were nausea (36%); diarrhea (29%); fatigue (18%); vomiting, anemia, and abdominal pain (13% each); and anorexia (11%) rrmlvcvggh (weikxirqay ) View more	Positive	15 Nov 2022
				acalabrutinib+MS-553 (Cohort B)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis